Quanterix Advances Spatial Biology Content Innovation Engine With New Cancer Research Tools
Quanterix Corporation (NASDAQ: QTRX) has reported further progress on its Content Innovation Engine, a strategic initiative introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026 to expand the breadth of spatial biology content available to researchers. The company is highlighting the latest developments at the European Society for Spatial Biology (ESSB) conference, taking place September 28 through October 1, 2026.
The updates demonstrate continued expansion of Quanterix’s spatial biology portfolio following the integration of Akoya Biosciences’ spatial biology platform with Quanterix’s established expertise in ultra-sensitive, quantitative immunoassay development through its SIMOA® technology.
The Content Innovation Engine is organized around the hallmarks of cancer framework, providing researchers with a biology-focused strategy for investigating multiple aspects of tumor biology within tissue. The approach is designed to help researchers extract more information from individual tissue sections by combining high-plex spatial analysis with targeted assay content addressing important biological pathways and interactions.
Quanterix is also extending the platform beyond discovery applications through capabilities spanning spatial instrumentation, assay and reagent development, quality systems, laboratory services and manufacturing. These capabilities are intended to support research programs progressing from early discovery through translational research and clinical applications.
Three Programs Advance From AACR Preview to Commercial Delivery
At AACR 2026, Quanterix previewed several additions to its spatial biology content roadmap. Since that meeting, three programs have progressed, with one now commercially available and two others confirmed for shipment during the fourth quarter of 2026.
The progress reflects the company’s stated objective of rapidly translating new assay concepts into products and services that researchers can use in spatial biology workflows.
The programs include the commercially launched PhenoCode™ 2.0 Molecular Barcoding Kit, the upcoming Tumor Immune Microenvironment (TIME) panel and a high-plex antibody-drug conjugate (ADC) panel designed to combine ADC and immuno-oncology measurements in a single tissue section.
Together, the offerings are intended to broaden the types of biological questions researchers can investigate using Quanterix’s spatial biology technologies.
PhenoCode 2.0 Molecular Barcoding Kit Now Available
The PhenoCode™ 2.0 Molecular Barcoding Kit has progressed from early access to full commercial availability and can now be ordered by researchers.
Built around PhenoCode 2.0 chemistry, the kit is designed to enable researchers to barcode virtually any antibody with high reliability and yield. The capability allows established antibody panels to be extended into additional research applications without requiring substantial changes to the existing workflow.
The flexibility of antibody barcoding can be particularly relevant in research programs that need to examine different combinations of biomarkers or adapt existing panels to specific biological questions. Quanterix said the kit can support applications across areas including immuno-oncology and neuroscience, as well as other fields of biomedical research.
By moving the technology into full commercial release, Quanterix is making the chemistry available for broader research use as part of its expanding spatial biology ecosystem.
TIME Panel Expands Tumor Immune Microenvironment Analysis
Another program advancing toward commercial availability is the TIME panel, which is scheduled to ship during the fourth quarter of 2026.
The content originated from a tertiary lymphoid structure component previewed at AACR as part of the IO60 Spike-In Module. During development, the scope of the content was expanded beyond tertiary lymphoid structure architecture to provide a broader assessment of the tumor immune microenvironment.
The resulting TIME panel is designed as a PhenoCycler®-Fusion spike-in module compatible with the PhenoCode Discovery IO60 panel.
Tumor immune microenvironment analysis is an important area of cancer research because tumors are composed not only of malignant cells but also of immune cells, stromal components and other cellular populations that can influence tumor progression and response to therapy. Understanding the spatial relationships among these components can provide researchers with information that may not be captured through conventional bulk molecular measurements.
The TIME panel is intended to give researchers an expanded view of these interactions within the tissue environment, supporting more detailed characterization of immune organization and tumor biology.
Quanterix has confirmed the panel for shipment in Q4 2026.
High-Plex ADC Panel Combines ADC and Immuno-Oncology Biology
A second PhenoCycler-Fusion spike-in module compatible with the IO60 panel is also scheduled for shipment during the fourth quarter of 2026.
The high-plex ADC panel is designed to enable researchers to measure antibody-drug conjugate target expression together with tumor immune contexture within the same tissue section.
ADC therapies have become an increasingly important area of oncology research, while immuno-oncology approaches continue to generate interest in combination treatment strategies. Understanding how ADC target expression relates to the surrounding immune environment can therefore be relevant to researchers investigating the biological mechanisms underlying these therapeutic approaches.
By enabling ADC and immune-related measurements in a single tissue section, the new panel is intended to address research needs at the intersection of ADC development and immuno-oncology.
The panel forms part of Quanterix’s broader effort to develop spatial content around specific biological questions rather than limiting researchers to standardized biomarker menus.
Accelerator Laboratory Expands Custom ADC Panel Development
Alongside its commercial assay content, Quanterix is expanding its custom development capabilities through the Accelerator Laboratory.
The laboratory has built experience in ADC combination biology through previous panel development efforts. Quanterix introduced a breast cancer ADC panel on the PhenoImager HT platform at AACR 2025 and subsequently presented two NSCLC ADC panels at AACR 2026.
According to the company, these programs have established a track record across three ADC panels covering two indications. The experience is now being extended into a custom ADC panel development service for biopharmaceutical and translational research teams.
Under the service, customers can define the specific indication, tissue type and biomarker set relevant to their research program. The Accelerator Laboratory then designs, optimizes and validates the panel according to the specified requirements.
This model provides an alternative to selecting only from predefined commercial panels. It allows research teams to develop spatial assays around the biological questions and therapeutic programs they are investigating.
From Discovery to Clinical Trial Testing
Custom ADC panel development is part of Quanterix’s broader fully managed tissue biomarker services.
The Accelerator Laboratory uses PhenoCycler-Fusion technology for high-plex biomarker discovery and characterization of the tumor microenvironment. Researchers can use this stage to investigate a broad range of markers and identify those that provide the most informative biological signals.
Selected markers can then be translated into targeted, high-throughput panels on the PhenoImager HT platform. These panels are designed for larger-cohort studies and clinical trial sample testing, creating a pathway from exploratory discovery to more focused biomarker analysis.
Quanterix said assays follow a tiered validation approach that can progress from research-use applications toward the analytical validation expected for clinical trial assays.
The Accelerator Laboratory operates within CLIA, GCLP and ISO 15189 quality frameworks and is supported by dedicated teams covering histology, pathology, quality assurance and project management.
This combination of laboratory infrastructure and spatial technologies is intended to support research teams that require more than instrumentation or individual reagents. It provides a managed workflow for tissue biomarker development, optimization and testing.
Building a Biology-Focused Spatial Research Platform
The Content Innovation Engine represents Quanterix’s effort to integrate spatial technology, assay development and biological content into a broader research platform.
The integration of Akoya Biosciences’ spatial biology capabilities with Quanterix’s experience in quantitative immunoassays provides the foundation for developing new tools aimed at extracting more information from tissue samples.
The company’s focus on the hallmarks of cancer provides a framework for organizing this content around biological processes relevant to cancer research. Rather than treating spatial assays solely as technology platforms, the strategy emphasizes the biological questions researchers need to answer.
Everett Cunningham, President and CEO of Quanterix, said the Content Innovation Engine represents a long-term investment in enabling researchers to investigate more of the biology present within an individual tissue section.
“What we’re showing at ESSB is that investment continuing to build out: new spike-in content that deepens tumor immune microenvironment profiling, and a custom development capability at the Accelerator Laboratory that lets us build ADC panels around what a researcher’s program actually needs, not a fixed menu,” Cunningham said.
He added that the company’s direction is focused on expanding both coverage and flexibility while organizing the platform around areas of importance in cancer research.
Continued Expansion of Spatial Biology Content
The latest product and service developments provide multiple routes for researchers to expand their use of spatial biology technologies.
The PhenoCode 2.0 Molecular Barcoding Kit is now commercially available, giving researchers greater flexibility in antibody barcoding and panel development. Meanwhile, the TIME panel and high-plex ADC panel are scheduled for Q4 2026 shipment, adding specialized content focused on tumor immune biology and ADC-immuno-oncology interactions.
At the same time, the Accelerator Laboratory’s custom development service provides biopharmaceutical and translational teams with an option to develop tailored ADC panels based on their specific research programs.
Together, these initiatives illustrate Quanterix’s efforts to build a broader spatial biology ecosystem spanning discovery, assay development, tissue characterization, translational research and clinical trial testing. The company is presenting these developments at ESSB 2026, where researchers can learn more about the new content and laboratory capabilities.
Quanterix is exhibiting at booth 17 during the ESSB conference and is providing additional information through its corporate website.
About Quanterix
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its SIMOA® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics.